T
Tempest Therapeutics, Inc. (TPST)
NCM – Real Time Price. Currency in USD
1.92
-0.02 (-1.03%)
At close: May 12, 2026, 4:00 PM EDT
1.92
0.00 (0.00%)
After-hours: May 12, 2026, 7:14 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.92
-0.02 (-1.03%)
At close: May 12, 2026, 4:00 PM EDT
1.92
0.00 (0.00%)
After-hours: May 12, 2026, 7:14 PM EDT
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
| Name | Position |
|---|---|
| Dr. Andrew Fang Ph.D. | Head of Business Development |
| Dr. Matthew Angel Ph.D. | President, CEO & Director |
| Mr. Justin Trojanowski CPA | Corporate Controller, Treasurer & Principal Accounting Officer |
| Mr. Nicholas Maestas | CFO, Head of Corporate Strategy & Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-05-06 | 8-K | d93617d8k.htm |
| 2026-04-08 | CORRESP | filename1.htm |
| 2026-04-02 | S-3 | d17525ds3.htm |
| 2026-04-01 | CORRESP | filename1.htm |
| 2026-03-31 | S-8 POS | d90534ds8pos.htm |
| 2026-03-30 | S-3 | d104843ds3.htm |
| 2026-03-23 | 8-K | d85035d8k.htm |
| 2026-02-25 | 8-K | d22967d8k.htm |
| 2026-02-11 | 8-K | d47566d8k.htm |
| 2026-02-06 | 8-K | d159400d8k.htm |